A review links urogenital microbial dysbiosis with cancer progression and with variability in immunotherapy responses, while calling for standardization to validate non-invasive microbiome-derived biomarkers. The work frames the urogenital tract as an immunologically active environment in which microbial community changes can influence tumor-immune dynamics. The authors argue that current findings are limited by heterogeneous study designs, sample handling, and biomarker validation approaches. They recommend standardized protocols to ensure that candidate microbial signals can be reproduced across cohorts and ultimately tested as non-invasive diagnostic or response-monitoring tools. For industry, the review supports continued interest in microbiome-biomarker programs but emphasizes that pipeline assets will need stronger analytical rigor and prospective validation. It also signals opportunities for companies integrating microbiome sequencing with clinical endpoints in oncology trials. (Story context: the article is positioned as a review focused on microbiota-biomarker translation hurdles.)
Get the Daily Brief